Ocrelizumab-Induced Severe Colitis
We report a case of severe ocrelizumab (anti-CD20 monoclonal antibody) induced colitis in a 43-year-old woman with multiple sclerosis leading to total colectomy after failing medical therapy. Histology of the colectomy was consistent with medication-induced colitis.
Main Authors: | Hsing Hwa Lee, Naveen Sritharan, Daniel Bermingham, Gabriela Strey |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2020-01-01
|
Series: | Case Reports in Gastrointestinal Medicine |
Online Access: | http://dx.doi.org/10.1155/2020/8858378 |
Similar Items
-
Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program.
by: Paul Emery, et al.
Published: (2014-01-01) -
The Effect of Ocrelizumab in the Treatment of Multipl Sclerosis
by: Şenay Yıldız Çelik
Published: (2017-09-01) -
The experience of using ocrelizumab in routine practice
by: E. V. Popova, et al.
Published: (2020-03-01) -
Ocrelizumab as a breakthrogh in multiple sclerosis treatment
by: Marcin Zaniuk, et al.
Published: (2021-05-01) -
Medication for multiple sclerosis : Ocrelizumab effect and safety
by: Oudah, Alsafa
Published: (2018)